Federal Register / Vol. 65, No. 117 / Friday, June 16, 2000 / Notices 37791

Dated: June 12, 2000.

Kathy Cahill,

Associate Director for Policy, Planning, and

Evaluation, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–15253 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00136]

Landmine Survivor Peer Support

Networks in Five Mine-Affected

Countries; Notice of Availability of

Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program for ‘‘Landmine Survivor Peer

Support Networks in Five MineAffected Countries’.

B. Eligible Applicant

Assistance will be provided only to

Landmine Survivors Network (LSN). No

other applications are solicited.

LSN is the most appropriate and

qualified organization for conducting

activities under this program because:

1. LSN has existing staff, both

domestically and internationally,

trained in public health and social

sciences related to landmine survivors.

2. LSN has a significant global

presence, allowing it to coordinate with

local governments and international

organizations in the implementation of

projects related to landmine survivors.

3. LSN has a singularly high level of

expertise and experience in working

with landmine survivor issues.

4. LSN has an existing field presence

including peer support networks in four

of the five countries identified in this

announcement (Bosnia, Ethiopia,

Mozambique and Jordan).

5. LSN has established itself as a

leader in the Non-Governmental

Organization (NGO) community as a

provider of support to individuals,

families, and communities injured by

landmines, giving it the resources and

contacts to implement the program with

the support of professional networks in

the NGO community.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $1,200,000 is available

in FY 2000 to fund this award. It is

expected that the award will begin on or

about September 30, 2000 and will be

made for a 12-month budget period

within a project period of up to 3 years.

D. Where To Obtain Additional

Information

Program technical assistance may be

obtained from: Brad Woodruff,

International Emergency and Refugee

Health Branch, National Center for

Environmental Health, Centers for

Disease Control and Prevention, 4770

Buford Highway, NE (F–48), Atlanta,

GA 30341–3724, Telephone number:

770–488–3523, Email address:

baw4@cdc.gov

Business management technical

assistance may be obtained from: Mattie

Jackson, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

Room 3000, 2920 Brandywine Road,

Atlanta, GA 30341–4146, Telephone

number: 770–488–2718, Email address:

mij3@cdc.gov

Dated: June 12, 2000.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 00–15251 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

CDC Advisory Committee on HIV and

STD Prevention: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Public Law 92–463), the Centers for

Disease Control and Prevention (CDC)

announces the following committee

meeting.

Name: CDC Advisory Committee on

HIV and STD Prevention.

Times and Dates:

8:30 a.m.–5 p.m., June 29, 2000.

8:30 a.m.–3 p.m., June 30, 2000.

Place: Marriott Atlanta Century

Center, 2000 Century Boulevard NE,

Atlanta, Georgia 30345.

Status: Open to the public, limited

only by the space available. The meeting

room will accommodate approximately

100 people.

Purpose: This Committee is charged

with advising the Director, CDC,

regarding objectives, strategies, and

priorities for HIV and STD prevention

efforts including maintaining

surveillance of HIV infection, AIDS, and

STDs, the epidemiologic and laboratory

study of HIV/AIDS and STDs,

information/education and risk

reduction activities designed to prevent

the spread of HIV and STDs, and other

preventive measures that become

available.

Matters To Be Discussed: Agenda

items include issues pertaining to (1)

national syphilis elimination efforts (2)

strategic planning for HIV Prevention

and (3) CDC’s HIV Prevention efforts in

Africa and India.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Paulette Ford, Committee Management

Analyst, National Center for HIV, STD,

and TB Prevention, 1600 Clifton Road,

NE, m/s E–07, Atlanta, Georgia 30333.

Telephone 404/639–8008, fax 404/639–

8600, e-mail pbf7@cdc.gov.

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

Notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: June 12, 2000.

John Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention.

[FR Doc. 00–15252 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1305]

Foods: ‘‘Apple Juice, Apple Juice

Concentrates, and Apple Juice

Products—Adulteration with Patulin;’’

Draft Compliance Policy Guide;

Availability and ‘‘Patulin in Apple

Juice, Apple Juice Concentrates, and

Apple Juice Products;’’ Draft

Supporting Document; Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a draft compliance policy

guide (CPG) entitled ‘‘Apple Juice,

Apple Juice Concentrates, and Apple

Juice Products—Adulteration with

37792 Federal Register / Vol. 65, No. 117 / Friday, June 16, 2000 / Notices

Patulin’’. This document is intended to

make FDA offices and industry aware of

FDA’s guidance for enforcement

concerning apple juice, apple juice

concentrates, and apple juice products

that contain patulin, a toxic substance

produced by molds that may grow on

apples, and that has been found to occur

at high levels in some apple juice

products offered for sale or import in

the United States. The agency is also

announcing the availability of a

document entitled ‘‘Patulin in Apple

Juice, Apple Juice Concentrates, and

Apple Juice Products’’ (the draft

supporting document).

DATES: Submit written comments by

August 15, 2000.

ADDRESSES: Submit written requests for

single copies of the draft CPG entitled

‘‘Apple Juice, Apple Juice Concentrates,

and Apple Juice Containing Products—

Adulteration with Patulin’’ and/or the

draft supporting document entitled

‘‘Patulin in Apple Juice, Apple Juice

Concentrates, and Apple Juice

Products’’ to Michael E. Kashtock

(address below). Send one selfaddressed adhesive label to assist that

office in processing your request. See

the SUPPLEMENTARY INFORMATION section

for electronic access to this document.

Submit written comments on the draft

CPG and the draft supporting document

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852. Comments

and requests for copies should be

identified with the docket number

found in brackets in the heading of this

document.

FOR FURTHER INFORMATION CONTACT:

Michael E. Kashtock, Center for Food

Safety and Applied Nutrition (CFSAN)

(HFS–305), Food and Drug

Administration, 200 C St. SW.,

Washington, DC 20204, 202–205–5321,

FAX 202–205–4422, e-mail:

mkashtoc@cfsan.fda.gov.

SUPPLEMENTARY INFORMATION: FDA has

developed a draft CPG on FDA’s

guidance for enforcement concerning

apple juice, apple juice concentrates,

and apple juice products that contain

patulin. This document is intended to

provide clear policy and regulatory

guidance to FDA’s field and

headquarters staff with regard to such

foods. In particular, if these products:

(1) Contain patulin at or above 50 parts

per billion (ppb) (the action level) based

on the level found or calculated to be

found in single strength apple juice,

reconstituted single strength apple juice

(if the food is an apple juice

concentrate), or the single strength

apple juice component of the product (if

the food contains apple juice as an

ingredient); and (2) the identity of

patulin is confirmed by gas

chromatography/mass spectrometry,

then the FDA field enforcement office

may consider whether to recommend

legal action against such apple juice,

apple juice concentrates, and apple

juice products in interstate commerce,

and it may consider whether to

recommend detention of the same

products when offered for import into

the United States. For the purposes of

this guidance, single strength juice is

100 percent juice that is unconcentrated

(see 21 CFR 101.30(h)). The scientific

basis for the 50 ppb action level is

presented in the draft supporting

document. The draft CPG also contains

information that may be useful to the

regulated industry and to the public.

FDA has included an import

specimen charge in this draft CPG to

assist its field personnel in

recommending refusal of admission for

imported goods when warranted. The

fact that this draft CPG contains an

import specimen charge (in addition to

the customary specimen charge

addressing regulatory action against

food in domestic commerce) does not

restrict any action FDA may take under

circumstances addressed by other CPG’s

that do not have an import specimen

charge, and it does not imply that FDA

will not take action when warranted.

The agency has adopted good

guidance practices (GGP’s) that set forth

the agency’s policies and procedures for

the development, issuance, and use of

guidance documents (62 FR 8961,

February 27, 1997). The draft CPG is

being issued as a level 1 draft guidance

consistent with GGP’s. The draft CPG

represents the agency’s current thinking

on its enforcement guidance concerning

the adulteration of apple juice, apple

juice concentrates, and apple juice

products with patulin. It does not create

or confer any rights for or on any person

and does not operate to bind FDA, or

the public. An alternative approach may

be used if such approach satisfies the

requirements of the applicable statute

and regulations.

Interested persons may submit to the

Dockets Management Branch (address

above) written comments regarding the

draft CPG and the draft supporting

document by August 15, 2000. Two

copies of any comments are to be

submitted, except that individuals may

submit one copy. Comments are to be

identified with the docket number

found in brackets in the heading of this

document. Received comments, the

draft CPG, and the draft supporting

document may be seen in the Dockets

Management Branch between 9 a.m. and

4 p.m., Monday through Friday. These

two documents may also be accessed at

the CFSAN home page on the Internet

at http://www.fda.cfsan.gov.

Dated: June 8, 2000.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 00–15122 Filed 6–15–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Care Financing Administration

Privacy Act of 1974; Report of Altered

Systems

AGENCY: Department of Health and

Human Services (HHS), Health Care

Financing Administration (HCFA).

ACTION: Notice of the modification or

alteration to 20 systems of records.

SUMMARY: In accordance with the

requirements of the Privacy Act of 1974,

we are correcting information provided

in 20 HCFA systems of records specified

in Appendix A. These systems are all

related to research or demonstration

projects under the control of the Office

of Strategic Planning. We are deleting

the published routine uses in the system

of records listed in Appendix A and

replacing them with four revised routine

uses. The routine uses are being

prioritized and renumbered accordingly.

We are taking the opportunity to update

those sections of the SORs that were

affected by the recent reorganization.

We are also updating the language in the

administrative sections to correspond

with language used in other HCFA

system of records.

The primary purpose of the

corrections to these systems is to

shorten the language, make the routine

uses easier to read, and provide clarity

to HCFA’s intention to disclose

individual-specific information related

to the purposes for which the

information is being collected.

EFFECTIVE DATES: HCFA filed a

correction to a system report with the

Chair of the House Committee on

Government Reform and Oversight, the

Chair of the Senate Committee on

Governmental Affairs, and the

Administrator, Office of Information

and Regulatory Affairs, Office of

Management and Budget (OMB) on June

12, 2000. To ensure that all parties have

adequate time in which to comment, the

corrected systems of records, including

routine uses, will become effective 40

days from the publication of the notice,

or from the date it was submitted to

OMB and the Congress, whichever is